AMD vs Bristol-Myers Squibb: Founders, CEOs and History
AMD was founded in 1969 by Jerry Sanders, Edwin Turney and is led by Lisa Su. Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner.
Company facts
AMD
- Founded
- 1969
- Headquarters
- Santa Clara, California
- Current CEO
- Lisa Su
- Employees
- 31,000
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Founders
AMD
Jerry Sanders
Advanced Micro Devices (AMD) was founded in May 1969 by Jerry Sanders, a charismatic, flamboyant electrical engineer, along with seven of his colleagues from Fairchild Semiconductor (the well-known incubator of Silicon Valley that also birthed Intel).
Edwin Turney
Edwin Turney helped establish the operating foundation behind AMD's early logic-device business. While Sanders became the public face, Turney's contribution was making sure the company could earn trust through production reliability and execution.
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
CEOs and their tenures
AMD
- Jerry Sanders1969–2002
CEO
Sanders, born in Chicago in 1936, worked at Douglas Aircraft and Motorola before joining Fairchild Semiconductor in 1961, where he rose to head worldwide sales and marketing.
Source - Hector Ruiz2002–2008
CEO
Ruiz grew up in Piedras Negras, Mexico, and as a teenager crossed the US border daily to attend high school in Eagle Pass, Texas, graduating valedictorian only three years after learning English.
Source - Dirk Meyer2008–2011
CEO
Meyer, a University of Illinois computer-engineering graduate with an MBA from Boston University, co-architected the Alpha 21064 and 21264 microprocessors at Digital Equipment Corporation before joining AMD in 1996, where he personally led development of the o…
Source - Rory Read2011–2014
CEO
Read spent 23 years at IBM in global leadership roles before becoming president and COO of Lenovo, and holds an information-sciences degree from Hartwick College.
Source - Lisa Su2014–present
CEO
Born in Taiwan and raised in the United States, Su earned bachelor's, master's and doctorate degrees in electrical engineering from MIT and worked at Texas Instruments, IBM and Freescale Semiconductor before joining AMD in 2012 as senior vice president of glob…
Source
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Timeline: AMD and Bristol-Myers Squibb side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1969AMD
Advanced Micro Devices Founded
Jerry Sanders and seven colleagues from Fairchild Semiconductor founded AMD on May 1, 1969, and broke ground that year on the 915 DeGuigne building in Sunnyvale, California, which remained the headquarters for more than 47 years.
1975AMD
Entry Into Microprocessors
AMD entered the microprocessor market in 1975, moving beyond the logic devices it started with. The decision put it into direct competition with Intel and made x86 compatibility the center of its business for the next four decades.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1999AMD
Athlon Breakthrough
Athlon launched in 1999 and matched or beat Intel on desktop performance. In March 2000 AMD announced the first 1 GHz x86 processor, days ahead of Intel, which changed how enthusiasts and PC makers judged the company.
2005AMD
Antitrust Lawsuit Against Intel
AMD sued Intel in 2005, alleging rebates and exclusionary practices that limited its access to PC makers.
2006AMD
ATI Technologies Acquired
AMD acquired ATI Technologies in 2006 for about $5.4B to add graphics and chipsets. The debt-funded deal strained the balance sheet just as Intel shipped Core 2, but ATI became the basis for Radeon graphics, console APUs, and later Instinct accelerators.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009AMD
Fabless Pivot Through GlobalFoundries
AMD moved its manufacturing operations into GlobalFoundries in 2009 and stopped owning fabs. The change removed billions of annual capital spending and let AMD buy leading-edge capacity, but it also tied the product roadmap to outside foundries.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011AMD
Bulldozer Architecture Failure
Bulldozer traded single-thread performance for core count at a time when most software depended on per-core speed. Reviews were poor, PC maker confidence fell, and server share collapsed, which is what forced the clean-sheet Zen project.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014AMD
Lisa Su Becomes CEO
AMD's board appointed Lisa Su president and CEO on October 8, 2014, succeeding Rory Read. She narrowed the company around high-performance computing and put the engineering budget behind the Zen CPU core rather than spreading it across incremental projects.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2017AMD
Ryzen, EPYC, and Chiplets Rebuild AMD
Zen reached the market in 2017 as Ryzen for desktops and EPYC for servers. Chiplet packaging over Infinity Fabric let AMD build high core-count parts from smaller dies, improving usable yield and giving it a cost structure Intel's monolithic designs could not…
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2022AMD
Xilinx Acquisition
AMD completed the Xilinx acquisition in February 2022. The all-stock deal was announced in October 2020 at about $35B and was worth roughly $49B at close.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025AMD
ZT Systems Acquired and Its Factories Sold
AMD closed the ZT Systems purchase on March 31, 2025, paying $3.2B in cash plus 8.3 million shares for rack-scale AI systems design.
2025AMD
OpenAI Agrees to Deploy 6 Gigawatts of AMD GPUs
On October 6, 2025 AMD and OpenAI announced a multi-year agreement covering 6 gigawatts of AMD GPUs, starting with a 1 gigawatt Instinct MI450 deployment in the second half of 2026.
2025AMD
Record $34.6B Revenue
AMD reported FY2025 revenue of $34.6B, up 34%, with net income of $4.3B and a 50% gross margin.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2026AMD
Meta Agrees to Deploy Up to 6 Gigawatts of AMD GPUs
On February 24, 2026 AMD and Meta announced a multi-year agreement for up to 6 gigawatts of Instinct GPUs.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
Acquisitions
AMD
- ZT Systems2025$4.9B
- Silo AI2024$665M
- Xilinx2022$49B
- Pensando Systems2022$1.9B
- ATI Technologies2006$5.4B
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Questions about AMD vs Bristol-Myers Squibb
Who is the CEO of Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company?
Advanced Micro Devices, Inc. is led by Lisa Su and Bristol-Myers Squibb Company is led by Christopher Boerner. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Advanced Micro Devices, Inc. founded vs Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company was founded in 1887 — 82 years before Advanced Micro Devices, Inc., which was founded in 1969. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Advanced Micro Devices, Inc..
How many employees does Advanced Micro Devices, Inc. have compared to Bristol-Myers Squibb Company?
Advanced Micro Devices, Inc. employs approximately 31,000 people, while Bristol-Myers Squibb Company employs approximately 32,500. Bristol-Myers Squibb Company has the larger workforce at 32,500 employees, compared to Advanced Micro Devices, Inc.'s 31,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company headquartered?
Both Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Advanced Micro Devices, Inc. and Bristol-Myers Squibb Company?
Advanced Micro Devices, Inc. was founded by Jerry Sanders, Edwin Turney. Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers.
Which company has a longer operating history — Advanced Micro Devices, Inc. or Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Advanced Micro Devices, Inc. has been in operation for around 57 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AMD vs Bristol-Myers Squibb overview